BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 23280481)

  • 1. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
    Chen CL; Mahalingam D; Osmulski P; Jadhav RR; Wang CM; Leach RJ; Chang TC; Weitman SD; Kumar AP; Sun L; Gaczynska ME; Thompson IM; Huang TH
    Prostate; 2013 Jun; 73(8):813-26. PubMed ID: 23280481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
    Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
    J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
    Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.
    Satelli A; Batth I; Brownlee Z; Mitra A; Zhou S; Noh H; Rojas CR; Li H; Meng QH; Li S
    Oncotarget; 2017 Jul; 8(30):49329-49337. PubMed ID: 28521303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer.
    Hamilton G; Rath B
    Adv Exp Med Biol; 2017; 994():229-245. PubMed ID: 28560677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
    Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
    Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.
    Markou A; Lazaridou M; Paraskevopoulos P; Chen S; Świerczewska M; Budna J; Kuske A; Gorges TM; Joosse SA; Kroneis T; Zabel M; Sedlmayr P; Alix-Panabières C; Pantel K; Lianidou ES
    Clin Chem; 2018 Feb; 64(2):297-306. PubMed ID: 29122836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
    Armstrong AJ; Marengo MS; Oltean S; Kemeny G; Bitting RL; Turnbull JD; Herold CI; Marcom PK; George DJ; Garcia-Blanco MA
    Mol Cancer Res; 2011 Aug; 9(8):997-1007. PubMed ID: 21665936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    Russo GI; Bier S; Hennenlotter J; Beger G; Pavlenco L; van de Flierdt J; Hauch S; Maas M; Walz S; Rausch S; Bedke J; Morgia G; Stenzl A; Todenhöfer T
    BJU Int; 2018 Jul; 122(1):152-159. PubMed ID: 29542849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.
    O'Hara SM; Moreno JG; Zweitzig DR; Gross S; Gomella LG; Terstappen LW
    Clin Chem; 2004 May; 50(5):826-35. PubMed ID: 14988224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells.
    Lin E; Rivera-Báez L; Fouladdel S; Yoon HJ; Guthrie S; Wieger J; Deol Y; Keller E; Sahai V; Simeone DM; Burness ML; Azizi E; Wicha MS; Nagrath S
    Cell Syst; 2017 Sep; 5(3):295-304.e4. PubMed ID: 28941584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.
    Miyamoto DT; Lee RJ; Stott SL; Ting DT; Wittner BS; Ulman M; Smas ME; Lord JB; Brannigan BW; Trautwein J; Bander NH; Wu CL; Sequist LV; Smith MR; Ramaswamy S; Toner M; Maheswaran S; Haber DA
    Cancer Discov; 2012 Nov; 2(11):995-1003. PubMed ID: 23093251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.